Auriga Downgrades Salix Pharmaceuticals (SLXP) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
Tweet
Share
E-mailGet Alerts SLXP Hot Sheet
Price: $172.81 --0%
Rating Summary:
7 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 20 | New: 35
Rating Summary:
7 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 20 | New: 35
Join SI Premium – FREE
Auriga downgraded Salix Pharmaceuticals (NASDAQ: SLXP) from Buy to Hold, price target lowered from $54 to $51.
For an analyst ratings summary and ratings history on Salix Pharmaceuticals click here. For more ratings news on Salix Pharmaceuticals click here.
Shares of Salix Pharmaceuticals closed at $50.01 yesterday.
For an analyst ratings summary and ratings history on Salix Pharmaceuticals click here. For more ratings news on Salix Pharmaceuticals click here.
Shares of Salix Pharmaceuticals closed at $50.01 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Kubota Corp (6326:JP) (KUBTY) to Sell
- DTE Energy (DTE) PT Raised to $134 at BMO Capital
- Ultra Clean (UCTT) PT Lowered to $135 at UBS, Buy Rating Maintained
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
AurigaSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
